Lonza
Lonza Builds Vitamin B3 Plant in China
Lonza announces long-term microbial manufacturing agreement with Celltech
Lonza Biologics and Vaccinex announces strategic alliance
Lonza's polymer intermediates division ready to start up as separate firm Polynt
Lonza is a Life Sciences driven chemical company headquartered in Switzerland, with sales of CHF 2.54 billion in 2002 and operating 18 production and R&D facilities in 8 countries.
Business strategy
After a thorough review, the management and the Board came to the conclusion that the most value-accretive strategic objective requires the focusing of Lonza on the life sciences sector by fully utilizing and further developing the biotechnology and chemicals capabilities.The sale of the Energy business at the end of 2001 has been in line with Lonza's strategy to focus on its life sciences oriented businesses.
| 1897 | Foundation of Lonza AG Electricity Works in Gampel, Valais (Switzerland), on the banks of river Lonza. The electricity was used to manufacture calcium carbide and acetylene. |
| 1909 | Lonza moves to Visp and manufactures synthetic fertilizers out of nitrogen, ammonia and Calcium carbide |
| 1920 | Production of nitric acid, ketene, and diketene starts. |
| 1956 | Start of Production of niacin, a vitamin of the B-group. |
| 1965 | Change of the raw material base from carbide to naphtha and further development of backwards integration: intermediates and additives for pharmaceuticals, agrochemicals, dyestuffs, colours, adhesives, etc. |
| 1969 | Lonza expands to the USA and starts its business with chemical specialties. |
| 1974 | Merger with Alusuisse and development into an internationally operating enterprise. |
| 1980 | Lonza starts its biotechnological business. |
| 1982 | Start of exclusive manufacturing of substances for pharmaceutical and agrochemical companies. |
| 1992 | Lonza acquires a biotechnological production facility (fermentation) in the Czech Republic. |
| 1996 | In Guangzhou, China, a joint venture is signed to build up a niacinamide plant primarily to satisfy the regional market needs. |
| 1996 | Lonza acquires Celltech Biologics (GB and USA) and expands into the business with mammalian cell cultures and monoclonal antibodies. |
| 1999 | Lonza is de-merged from the Alusuisse-Lonza Group and listed as an independent company at the Swiss stock exchange. |
| 2001 | The sale of the Energy business - strategy to focus on its life sciences oriented businesses |
Lonza unit ready to start
up as separate firm
The
polymer intermediates division of Switzerland's Lonza group was
ready to start doing business on its own as soon as early
October, a source familiar with the business told Platts on the
sidelines of the EPCA 2006 meeting. The company, to be called Polynt, could start operating as a
separate entity by October 9, the source said.
Polynt would handle products previously managed by Lonza,
including plasticizers, phthalic anhydride
and maleic anhydride.
ロンザＧ、バイオ事業拡大へ積極策打ち出す
ロンザグループはバイオテクノロジー分野の事業拡大を目指す。このほど英セルテックと抗体フラグメントを受託生産することで合意した。他方、米バシネックス社と抗体探索サービスで戦略的提携を結んだ。
Lonza announces long-term
microbial manufacturing agreement with Celltech
http://www.lonza.com/group/en/news/medianews/lonza32.html
Lonza Group Ltd announces today that it has entered into a long-term supply agreement with Celltech Group plc, under which Lonza Biotec will manufacture PEGylated antibody fragment-based drugs for Celltech at its production facility for microbial biopharmaceuticals. Lonza and Celltech also announce the settlement of CDP 571 agreement.
2003/7/11 Lonza
Lonza Biologics and Vaccinex announces strategic alliance
http://www.lonza.com/group/en/news/medianews/lonza31.html
Lonza Biologics (Lonza) and Vaccinex, Inc. today announced a strategic alliance that offers their respective clients a broad range of antibody discovery and manufacturing services.